vs
Side-by-side financial comparison of BIOMERICA INC (BMRA) and CXApp Inc. (CXAI). Click either name above to swap in a different company.
BIOMERICA INC is the larger business by last-quarter revenue ($1.2M vs $1.0M, roughly 1.2× CXApp Inc.). BIOMERICA INC runs the higher net margin — -109.1% vs -544.1%, a 435.0% gap on every dollar of revenue. On growth, BIOMERICA INC posted the faster year-over-year revenue change (-26.0% vs -38.5%). Over the past eight quarters, BIOMERICA INC's revenue compounded faster (-12.1% CAGR vs -25.0%).
Biomerica Inc. is a global medical technology company that develops, manufactures and markets diagnostic test kits and related medical products. Its portfolio covers gastrointestinal conditions, infectious diseases, food intolerances and point-of-care testing solutions, serving clinical labs, healthcare providers and retail healthcare segments across North America, Europe and Asia.
CXApp Inc. is a technology firm specializing in digital workplace experience solutions. It offers cloud-based software tools for employee engagement, office space optimization, visitor management, and hybrid work coordination, serving mid-to-large enterprises across North America, APAC and Europe.
BMRA vs CXAI — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.0M |
| Net Profit | $-1.3M | $-5.6M |
| Gross Margin | 4.2% | 86.9% |
| Operating Margin | -113.5% | -576.9% |
| Net Margin | -109.1% | -544.1% |
| Revenue YoY | -26.0% | -38.5% |
| Net Profit YoY | -38.9% | -56.7% |
| EPS (diluted) | $-0.45 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | $1.0M | ||
| Q3 25 | $1.4M | $1.1M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | $1.1M | $1.2M | ||
| Q4 24 | $1.6M | $1.7M | ||
| Q3 24 | $1.8M | $1.9M | ||
| Q2 24 | $1.1M | $1.8M | ||
| Q1 24 | $1.0M | $1.8M |
| Q4 25 | $-1.3M | $-5.6M | ||
| Q3 25 | $2.0K | $-3.2M | ||
| Q2 25 | — | $-3.1M | ||
| Q1 25 | $-1.2M | $-1.6M | ||
| Q4 24 | $-950.0K | $-3.5M | ||
| Q3 24 | $-1.3M | $-5.4M | ||
| Q2 24 | $-1.4M | $-5.3M | ||
| Q1 24 | $-1.9M | $-5.2M |
| Q4 25 | 4.2% | 86.9% | ||
| Q3 25 | 30.7% | 89.0% | ||
| Q2 25 | — | 86.0% | ||
| Q1 25 | 1.7% | 87.7% | ||
| Q4 24 | 26.7% | 86.0% | ||
| Q3 24 | 16.0% | 80.4% | ||
| Q2 24 | 2.1% | 80.0% | ||
| Q1 24 | -14.7% | 82.0% |
| Q4 25 | -113.5% | -576.9% | ||
| Q3 25 | -81.0% | -343.4% | ||
| Q2 25 | — | -336.1% | ||
| Q1 25 | -108.1% | -306.0% | ||
| Q4 24 | -60.7% | -169.7% | ||
| Q3 24 | -75.7% | -194.3% | ||
| Q2 24 | -136.6% | -206.7% | ||
| Q1 24 | -196.7% | -197.3% |
| Q4 25 | -109.1% | -544.1% | ||
| Q3 25 | 0.1% | -283.4% | ||
| Q2 25 | — | -256.7% | ||
| Q1 25 | -103.9% | -132.0% | ||
| Q4 24 | -58.1% | -213.6% | ||
| Q3 24 | -72.8% | -286.5% | ||
| Q2 24 | -127.1% | -297.6% | ||
| Q1 24 | -188.6% | -284.4% |
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-0.48 | — | ||
| Q4 24 | $-0.06 | — | ||
| Q3 24 | $-0.63 | — | ||
| Q2 24 | $-2.57 | — | ||
| Q1 24 | $-0.11 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | $11.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.4M | $14.0M |
| Total Assets | $6.0M | $32.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.5M | $11.1M | ||
| Q3 25 | $3.1M | $5.1M | ||
| Q2 25 | — | $4.9M | ||
| Q1 25 | $3.1M | $3.9M | ||
| Q4 24 | $2.4M | $4.9M | ||
| Q3 24 | $2.8M | — | ||
| Q2 24 | $4.2M | — | ||
| Q1 24 | $5.3M | — |
| Q4 25 | $4.4M | $14.0M | ||
| Q3 25 | $5.2M | $15.2M | ||
| Q2 25 | — | $14.3M | ||
| Q1 25 | $5.5M | $15.6M | ||
| Q4 24 | $5.1M | $15.6M | ||
| Q3 24 | $5.3M | $13.6M | ||
| Q2 24 | $6.6M | $16.3M | ||
| Q1 24 | $7.8M | $20.9M |
| Q4 25 | $6.0M | $32.4M | ||
| Q3 25 | $6.9M | $28.5M | ||
| Q2 25 | — | $29.6M | ||
| Q1 25 | $7.4M | $29.3M | ||
| Q4 24 | $7.3M | $31.8M | ||
| Q3 24 | $7.9M | — | ||
| Q2 24 | $9.3M | — | ||
| Q1 24 | $10.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-991.0K | $-3.6M |
| Free Cash FlowOCF − Capex | — | $-3.6M |
| FCF MarginFCF / Revenue | — | -355.5% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-10.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-991.0K | $-3.6M | ||
| Q3 25 | $-268.0K | $-2.8M | ||
| Q2 25 | — | $-3.0M | ||
| Q1 25 | $-1.0M | $-979.0K | ||
| Q4 24 | $-791.0K | $-2.7M | ||
| Q3 24 | $-1.3M | $-2.1M | ||
| Q2 24 | $-1.0M | $-1.9M | ||
| Q1 24 | $-1.8M | $-650.0K |
| Q4 25 | — | $-3.6M | ||
| Q3 25 | — | $-2.8M | ||
| Q2 25 | — | $-3.0M | ||
| Q1 25 | — | $-984.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.1M | ||
| Q2 24 | $-1.1M | $-1.9M | ||
| Q1 24 | — | $-668.0K |
| Q4 25 | — | -355.5% | ||
| Q3 25 | — | -248.1% | ||
| Q2 25 | — | -247.2% | ||
| Q1 25 | — | -80.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -109.3% | ||
| Q2 24 | -95.5% | -108.6% | ||
| Q1 24 | — | -36.7% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | 2.1% | 0.5% | ||
| Q1 24 | 0.0% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | -134.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
